• Molecular NameMiglustat
  • SynonymNA
  • Weight219.281
  • Drugbank_IDDB00419
  • ACS_NO72599-27-0
  • Show 3D model
  • LogP (experiment)-1.087
  • LogP (predicted, AB/LogP v2.0)-1.44
  • pkaN/A
  • LogD (pH=7, predicted)-1.54
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-0.02
  • LogSw (predicted, AB/LogsW2.0)202.18
  • Sw (mg/ml) (predicted, ACD/Labs)102.79
  • No.of HBond Donors4
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds4
  • TPSA84.16
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyUsed primarily to treat Type 1 Gaucher disease (GD1).
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability97.0
  • Protein binding0.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNegligible
  • Half life6~7 h
  • ExcretionRenal, unchanged
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAdverse events observed in the HIV studies included granulocytopenia, dizziness, and paresthesia. Leukopenia and neutropenia have also been observed in a similar group of patients receiving 800 mg/day or above.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A